Somatostatin analogue in short term management of hyperinsulinism

J M W KIRK, L DI SILVIO, P C HINDMARSH, AND C G D BROOK
Endocrine Unit, Middlesex Hospital, London

SUMMARY Five infants with hypoglycaemia due to hyperinsulinism were treated for between three and 11 days with a somatostatin analogue, which raised the mean blood glucose concentration and lowered the glucose requirements in all. Somatostatin analogue appears to be useful in the short term management of these patients.

The prompt and effective treatment of hypoglycaemia due to hyperinsulinism reduces substantially the risk of long term neurological sequelae. Glucose alone, even in high concentrations, may often fail to maintain blood glucose concentrations within the normal range and other measures are required to reduce the excessive concentrations of insulin.

Diazenoxide has been used but this drug has major side effects and may be ineffective, especially in younger patients. Natural sequence somatostatin reduces insulin concentrations but its therapeutic use is limited by its half life of only two to three minutes so that it is necessary to administer it by continuous intravenous infusion.

We have used long acting somatostatin analogue (SMS 201–995, Sandoz), which is more potent and specific than the natural peptide and can be given by subcutaneous injection, to treat five patients with hypoglycaemia due to hyperinsulinism.

Patients and methods

All patients were girls: four presented within a few hours of birth; the fifth presented at 9 months of age but gave a history from birth of hypoglycaemic symptoms, which had responded to two hourly feeds both day and night. Birth weights were above the 50th centile for gestational age (table).

Spontaneous hypoglycaemia with inappropriately raised concentrations of insulin and without ketonuria was confirmed in all patients. Four proceeded to laparotomy with subtotal (95–98%) pancreatectomy; histological features of nesidioblastosis were seen in three specimens and the fourth had those of insulinoma. The fifth patient, whose blood glucose concentrations were easier to control than those of the other patients, recovered normal blood glucose concentrations over a period of several weeks.

Blood glucose concentrations were measured hourly using the YSI Model 23A Glucose Analyser (Yellow Spring Instruments). Plasma insulin concentrations were estimated by a two antibody immunoassay.

Results

A test dose of somatostatin analogue (1·0 μg) was administered subcutaneously to patient 1. Within minutes there was a rapid rise in blood glucose concentration and a concomitant reduction in glucose requirements, with the effect waning after four to five hours.

Somatostatin analogue was then administered subcutaneously in three to four doses per day, commencing at 1·0 μg/kg/dose, but subsequently titrating the dosage against response, for a total of three to 11 days. Increasing doses of analogue led to a fall in glucose requirements (although never into the normal range for infants of 4–6 mg/kg/minute) and to a reduction of glucose oscillation. All patients continued to require intravenous treatment.

The figure (a) shows that in all patients the mean 24 hour blood glucose concentration rose after the administration of somatostatin analogue (4–9 μg/kg/day). The change in mean 24 hour blood glucose concentrations was significant (Wilcoxon’s paired test; p<0·05), although the change in glucose oscillation was not. Glucose requirements fell significantly (p<0·05) (figure (b)).

Table Details of patients

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Age at presentation</th>
<th>Birth weight (g)</th>
<th>Gestation (weeks)</th>
<th>Glucose (mmol/l)</th>
<th>Insulin (mU/l)</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Birth</td>
<td>2610</td>
<td>36</td>
<td>0·4</td>
<td>24·1</td>
<td>Nesidioblastosis</td>
</tr>
<tr>
<td>2</td>
<td>Birth</td>
<td>4380</td>
<td>36</td>
<td>1·1</td>
<td>29·0</td>
<td>Nesidioblastosis</td>
</tr>
<tr>
<td>3</td>
<td>9 months</td>
<td>4000</td>
<td>40</td>
<td>1·5</td>
<td>21·1</td>
<td>Nesidioblastosis</td>
</tr>
<tr>
<td>4</td>
<td>Birth</td>
<td>4460</td>
<td>39</td>
<td>0·5</td>
<td>72·0</td>
<td>Insulinoma</td>
</tr>
<tr>
<td>5</td>
<td>Birth</td>
<td>2970</td>
<td>36</td>
<td>0·8</td>
<td>26·2</td>
<td>'Transient' hyperinsulinism</td>
</tr>
</tbody>
</table>
Recurrent pancreatoblastoma with inappropriate adrenocorticotropic hormone secretion

S J PASSMORE, P J BERRY, AND A OAKHILL

Bristol Royal Hospital for Sick Children, St Michael's Hill, Bristol

SUMMARY We describe a boy with recurrent pancreatoblastoma who developed Cushing's syndrome due to inappropriate adrenocorticotropic hormone secretion.

Primary epithelial tumours of the pancreas are rare in childhood. Although islet cell tumours have previously been shown to produce inappropriate secretion of peptide hormones, we believe that this is the first report of a pancreatoblastoma producing adrenocorticotropic hormone and an ectopic hormone syndrome.

Case report

A 22 month old boy presented with a firm, non-